Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Medicines Co (NASDAQ:MDCO)

Delayed Data
As of Oct 21
 -0.18 / -0.49%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Other

Company Description

The Medicines Co. is a biopharmaceutical company, which focuses on advancing the treatment of critical care patients through the delivery of medicines to the worldwide hospital marketplace. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria; Orbactiv for the treatment of acute bacterial skin and skin structure infections; Orbactiv for the treatment of acute bacterial skin and skin structure infections; PreveLeak, a mechanical vascular and surgical sealant; ready-to-use formulation of Argatroban for the treatment of thrombosis; and Recothrom, a human recombinant thrombin used as an aid to hemostasis, as well as acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases. Its development stage products include Cangrelor for the prevention of platelet activation and aggregation; IONSYS for the short-term management of acute postoperative pain; Raplixa, a dry powder topical formulation of fibrogen and thrombin; and RPX-602 for the treatment of bacterial infections. The company's products under development also comprise ABP-700, an intravenous anesthetic agent for moderate or deep sedation and general anesthesia in patients undergoing diagnostic or therapeutic procedures; ALN-PCSsc for the treatment of hypercholesterolemia; Carbavance, an antibiotic agent for the treatment of hospitalized patients with bacterial infections; and MDCO-216, a novel biologic, is a complex of a phospholipid and recombinantly manufactured ApoA-1 Milano, a naturally occurring variant of ApoA-1, a protein found in human high-density lipoprotein. Medicines was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ.

Contact Information

The Medicines Co.
8 Sylvan Way
Parsippany New Jersey 07054-3801
P:(973) 290-6000
Investor Relations:
(973) 290-6122



Mutual fund holders68.37%
Other institutional50.07%
Individual stakeholders13.90%

Top Executives

Clive A. MeanwellChief Executive Officer & Director
Stuart Anthony KingsleyPresident & Chief Operating Officer
William Bernard O'ConnorSVP, Chief Financial & Accounting Officer
David KallendVice President & Global Medical Director
John W. VilligerExecutive Vice President